Vestar Inc. of San Dimas, Calif., named to its board of directorsJames D. Watkins, former secretary of energy under the Bushadministration. Vestar also named Roger Crossley, presidentand chief executive officer, to the additional post of chairmanof the board.
BioCryst Pharmaceuticals Inc. of Birmingham, Ala., namedRonald E. Gray chief financial officer. Gray was chief financialofficer and secretary of Image Data Corp.
Michael Hitchcock was named director for project managementat Gilead Sciences Inc. of Foster City, Calif. He was director ofproject planning and mangement for all infectious diseaseprojects at Bristol-Myers Squibb Pharmaceutical ResearchInstitute.
The Liposome Company Inc. of Princeton, N.J., promotedAndrew S. Janoff to vice president, research, from executivedirector, research, and Joel B. Portnoff to vice president,development, from executive director, development. Thecompany also named David G. Shand, executive vice presidentof research and development and chief scientific officer, to itsboard of directors.
Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y., promotedJesse M. Cedarbaum to vice president, clinical affairs, fromprogram director of the company's clinical affairs group.Randall G. Rupp was promoted to vice president, manufacturingand process science, from director of manufacturing.
Matrix Pharmaceutical Inc. of Menlo Park, Calif., named to itsboard of directors Julius L. Pericola, a former senior executiveof the Bristol-Myers Squibb Co.
(c) 1997 American Health Consultants. All rights reserved.